FilingSEC EDGAR6-K
PolyPid Regains European Commercialization Rights for D-PLEX100
· SEC accepted
StageRights Reversion
Filing content
The company terminated its license agreement with Mercury Pharma and regained exclusive European commercialization rights for D-PLEX100, aiming to pursue new partnership opportunities.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…